Natural Capsules Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
NATCAPSUQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natural Capsules Limited announced unaudited financial results for Q3 and 9M FY26 ended December 31, 2025. Standalone revenue from operations fell to Rs. 3,414.64 lakhs (down ~21% YoY from Rs. 4,341.18 lakhs), while standalone net profit dropped sharply to Rs. 36.23 lakhs (vs Rs. 170.32 lakhs in Q3FY25). On a consolidated basis, the company swung to a net loss of Rs. 77.77 lakhs in Q3FY26 (from a profit of Rs. 10.57 lakhs in Q3FY25), driven by steep losses in the API segment (Rs. 640.27 lakhs in Q3 vs Rs. 47.45 lakhs loss YoY) as its new subsidiary Natural Biogenex is in early-stage operations. The board also allotted 45,000 equity shares via ESOP exercise (paid-up capital rose to Rs. 10.38 crore) and approved a postal ballot to enhance borrowing limits under Section 186 of the Companies Act. One manufacturing unit was temporarily shut from December 26 due to a regulatory issue and resumed January 30, 2026.
Short-term negative sentiment likely due to sharp YoY decline in standalone profitability and consolidated swing to losses, partly explained by regulatory shutdown of a unit and ramp-up costs at subsidiary. Shareholders may see this as a transitional quarter rather than structural weakness, but the API segment's mounting losses and regulatory disruption warrant close monitoring.